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Differential intraluminal and extraluminal activation of the hyperten-
sive endothelium by acetyicholine and endothelin-1. Y. Dohi, F.R.
Bühler, T.F. Lflscher, Departement Forschung, Labor Gefiissfors-
chung und Hypertonie, Departement Medizin, Abteilung Kardiologie,
Kanronsspital Basel, Switzerland. This study was designed to investi-
gate effects of intraluminal and extraluminal endothelin and acetyicho-
line in mesenteric resistance arteries of normotensive and hypertensive
rats. The third branches of mesenteric arteries (200 tm) were isolated
from 16 to 20 week old Wistar Kyoto rats (WKY) and spontaneously
hypertensive rats (SHR). The arteries were mounted on glass micro-
cannulae in organ chambers, and perfused and pressurized at 30 mm
Hg. Changes in intraluminal diameter were continuously measured
using a video dimension analyzer. Extraluminal endothelin- I evoked
concentration-dependent contractions of arteries with endothelium.
The sensitivity, but not the maximal response to endothelin-l was
smaller in SHR than in WKY. Removal of the endothelium enhanced
the contraction to a greater extent in SHR (25-fold) as compared to
WKY (6-fold). In arteries without endothelium, the sensitivity (pD2
value) to endothelin-l remained smaller in SHR (10.0 0.1) as
compared to WKY (10.9 0.4; P < 0.05), while that to norepinephrine
was similar. Extraluminal acetyicholine caused endothelium-dependent
relaxation in arteries contracted half-maximally with endothelin- 1. The
sensitivity was higher in SHR (7.8 0.1) than in WKY (7.0 0.1; P <
0.01). Low concentrations of intraluminal endothelin-1 (10'°-10 M)
evoked relaxations in WKY (14 2%), but not in SHR which were
prevented by indomethacin. Higher concentration of endothelin-1 (10—s
M) caused contraction, but the contraction was smaller than that
induced by extraluminal endothelin-l in both strains. After removal of
the endothelium, vasoconstrictor responses to intra- and extraluminal
endothelin-l were comparable in the two groups. Intraluminal acetyl-
choline caused endothelium-dependent relaxation, but the sensitivity
and the maximal response were smaller in SHR (7.8 0.1, 95 2%)
than in WKY (8.3 0.1, 102 2%; P < 0.01). In conclusion,
intraluminal, but not extraluminal activation of the endothelium with
endothelin-l and acetylcholine is impaired in resistance arteries of
SHR, indicating a selective defect of the inner surface of the endothe-
hum which is most exposed to high blood pressure. In addition,
vascular smooth muscle of SHR exhibits a reduced responsiveness to
endothelin- 1.
Involvement of parathyroid hormone in the progression of chronic
renal failure induced by high protein diet. T. Shigematsu, J. Caverzasio,
J-P. Bonjour, Division of Clinical Pathophysiology, Department of
Medicine, University of Geneva, Switzerland. Parathyroid hormone
(PTH) and high protein intake are considered to be two independent
factors involved in the progression of chronic renal insufficiency. In the
present study we examined whether PTH could be implicated in high
protein diet-induced progression of renal failure. Either sham operation
(S) or parathyroidectomy (PTX) was performed in 200 10 g male
Wistar rats prior to a two-step 5/6 nephrectomy (NX). After 7 day
recovery, NX-S and NX-PTX rats were pair-fed a high protein (HPr)
(40% casein) diet containing 0.8% P and 1.2% Ca. A group of NX-S rats
were pair-fed an isocaloric diet containing a normal protein (NPr) (20%
casein) content and the same amount of P and Ca. The results indicate
that PTX markedly improved the survival rate and prevented the
deterioration of renal functions induced by the HPr diet. The number of
rats alive after 33 weeks was 0/11, 6/10, and 9/10 in NX-S-HPr,
NX-PTX-HPr and NX-NPr, respectively. Associated with this im-
provement in the survival rate, the rise in blood urea nitrogen (BUN)
and plasma creatinine were consistently delayed or prevented in
NX-PTX as compared to NX-S rats fed the HPr diet. PTX also
prevented the decline in GFR induced by the HPr diet. Thus, the
clearance of inulin (C1,) was 0.17 0.02 and 2.17 0.20 mllmin in
NX-S-HPr and NX-PTX-HPr, respectively, P < 0.001, whereas it was
2.03 0.16 mI/mm in the NX-NPr group. PTX also prevented the
reduction in the fractional Na reabsorption induced by HPr (NX-PTX-
HPr: 97.8 0.3% and NX-S-HPr: 82.5 3.9%; P < 0.001). Similar
results were observed for the fractional reabsorption of Pi and Ca. The
kidney wet weight was 5.09 0.44 gin NX-S-HPr and 1.85 0.08 gin
NX-PTX-HPr, P <0.001, as compared to 2.41 0.12 gin NX-NPr rats,
P < 0.001. Thus, the increase in renal mass induced by HPr was
completely abolished by PTX. Finally the kidney calcium content was
significantly lower in NX-PTX-HPr rats (61.3 9.2 mol/g as compared
to NX-S-HPr animals (143.2 14.9 molJg, P < 0.001) but similar to
that determined in control NX-NPr value (76.0 16.3 mol/g). In
conclusion, PTX can prevent the progression of kidney damage due to
high protein diet in the subtotal nephrectomized rat model of chronic
renal failure. Whether this protective effect of PTX is related to the
disappearance of PTH per se or consequent to alterations in extracel-
lular calcium concentration remains to be elucidated.
Endotoxin increases intraglomerular resistance by a prostaglandin
dependent mechanism. H.A. Bock, M. Hermie, V. Muller, F.P. Brun-
ner, G. Thiel. Abteilung Nephrologie, Kantonsspital Base!, Switzer-
land. Endotoxin-induced mesangial contraction is thought to play a role
in the impairment of renal function which accompanies bacterial
endotoxemia. We used the isolated glomerular perfusion technique (Am
J Physiol 27:Fl460, 1990) to directly study endotoxin effects on
glomerular microcirculation. Single microdissected rabbit glomeruli
with intact Bowman's capsule were perfused through the afferent
arteriole with an electrolyte/albumin solution. The perfusion pipet in the
afferent arteriole was advanced to the glomerular tuft or even into it.
Perfusion pressure was maintained at 40 mm Hg, perfusion rate was
determined with FITC-labeled dextran, and glomerular volume was
calculated from planimetry. After two 20-minute control periods (Con.
1 and 2), Pseudomonas endotoxin (60 g/ml) was added to the perfusion
solution during three 20-minute periods (Exp. 1-3). In additional exper-




Resistance Volume Resistance Volume
Period mm Hg/,al/' ft mm Hg/pJ/' ft
Con. 1 38 5 996 155 31 8 1449 142
Con. 2 45 6 1007 166 32 8 1450 124
Exp. 1 52 6b 991 165" 34 7 1385 116
Exp. 2 62 l0 941 163k' 33 8 1457 Ill
Exp. 3 66 13 928 l58 32 7 1464 114
N 7 6 4 4
P value <0.0005 <0.02 NS NS
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Exp. 1 39 5 985 82
Exp. 2 35 a 989 92
Exp. 3 35 7 969 89
N 5 5
P value <0.05 NS
Data are means SE. a Significantly
periods, b from one control period.
different from both control
Similar changes of glomerular resistance and size as with endotoxin
were observed during perfusion with angiotensin II (l0 M, N = 6). We
conclude that Pseudomonas endotoxin applied to the glomerular lumen
causes a near doubling of glomerular resistance. Since efferent arterio-
lar constriction would increase glomerular size and afferent arteriolar
resistance is eliminated by design, the resistance increase has to be
intraglomerular, the most likely mechanism being mesangial contrac-
tion. The present data are, therefore, consistent with the concept that
endotoxin induces mesangial contraction by releasing vasoconstrictor
prostaglandins such as thromboxane. In addition, they suggest that
mesangial contraction may be more relevant for renal hemodynamics
than previously thought.
Expression of human recombinant lipocortin i in wheat germ cell-free
system and Xenopus oocytes: Lipocortin is not secreted. B .M. Frey, V.R.
Lingappa, H, Trachsel, F.J. Frey, Departments of Physiology and
Medicine, University of California, San Francisco, California, USA,
and Medizinische Polik/inik and Institul für Biochemie and Molekular-
biologic der Universitat Bern, Switzerland. Glucocorticoids are widely
used as immunosuppressive agents in nephrology. It was suggested that
the antiinflammatory action of glucocorticoids is due to the inhibition of
extracellular phospholipase A2 by lipocortin I. This mode of action is
hard to reconcile with the absence of a typical signal sequence of
lipocortin 1, which is usually present in proteins entering the secretory
pathway. In the present investigation the translocation of lipocortin I
across membranes was analyzed in a cell-free system and in Xenopus
oocytes. Based on the published sequence the cDNA we have cloned
and expressed human lipocortin I in E. coli. Lipocortin I was purified
and used to raise monoclonal antibodies. To test whether lipocortin I is
secreted, in vitro transcribed lipocortin mRNA was translated in a
wheat germ cell-free system in the absence and presence of microsomal
membranes. Prolactin mRNA was used as a control for translocation of
newly synthesized protein into membrane vesicles. Prolactin, but not
lipocortin I, was translocated into the membranes. To test for secretion
of lipocortin I in vivo, Xenopus oocytes were coinjected with tran-
scripts encoding lipocortin I and prolactin with and without the signal
sequence. Prolactin with the signal sequence was released into the
medium. However, neither prolactin without a signal sequence nor
lipocortin I were released. Carbonate extraction, using an integral
transmembrane protein as control, revealed no evidence for membrane
integration of lipocortin I. Thus the present results indicate that
lipocortin I is not a secreted protein and therefore cannot account for
extracellular inhibition of the phospholipase A2.
Etiology and prognosis of acute renal failure in Basel 1980-89. M.
Gregor, G. Thiel, Abt. Nephrologie, Departement Innere Medizin,
Kantonsspital und Universitãt Basel, Switzerland. We examined the
etiology (et) and prognosis of dialysis-dependent acute renal failure
(dARF) in 219 patients with 224 episodes of dARF. The most common
cause of dARF (109/224 = 49%) was hypotension ("shock-kidney") of
different et: 1) septic shock (69 = 30% of all dARF or about 2/3 of all
"shock-kidneys"), 2) heart failure (19), 3) hypovolemic shock (18), 4)
other or unknown (3). dARF induced by drugs followed on second place
(27 = 12%): antibiotics (11), NSAID (5), cyclosporin A (3), diuretics (2)
and others (6). The remaining 88 cases had heterogeneous et: pyelone-
phritis (14), rhabdomyolysis/hemolysis (10), postrenal obstruction (7),
hepatorenal syndrome (7), contrast media (6), glomerulonephritis (4),
malignant hypertension (4), parainfectious (4), thrombotic microangi-
opathy (3), Wegener's disease (3), myeloma (3), HELLP-syndrome (2),
sclerodermia (2), major burns, acute pancreatitis, HgCI2-intoxication,
embolization of renal arteries, hypercalcemia, dehydration, malako-
plakia, snake bite (each 1), unclear (10). Total mortality was 58% but
varied with et: hepatorenal syndrome and Wegener's disease (100%),
septic shock (88%), hypovolemic shock (78%), heart failure with dARF
(63%), drug induced dARF (41%), pyelonephritis (28%). Malignant
hypertension with dARF, thrombotic microangiopathy, HELLP-syn-
drome and contrast media induced dARF had no mortality. Overall
mortality was related primarily to the underlying disease. No patient
died due to acute renal failure. 14 patients (6%) remained dialysis
dependent, diagnoses being: malignant hypertension (4), glomerulone-
phritis (2), myeloma, thrombotic microangiopathy, sclerodermia and
malakoplakia (each 1), patients with preexisting chronic renal failure
(4). Conclusion: The most common causes of dARF were shock (49%)
and drugs (12%), The mortality of dARF was high (58%) mainly due to
the poor prognosis of the most common etiology (shock: mortality
82%). Other etiologies showed good prognosis and only a few cases
remained dialysis dependent (6%).
Interstitial nephritis (IN) with renal failure: Presentation and outcome.
C. Zehnder, A. Blumberg, Kantonsspital, 5000 Aarau, Switzerland.
The clinical presentation and outcome of 13 episodes of biopsy-proven
IN with oliguric renal failure (RF) in 12 patients (pts) (3 men), aged 16
to 72 years, were studied. Previous drug intake—cephalosporins,
cotrimoxazole, ciprofioxacin, penicillin, phenylbutazone, mefenamic
acid (2), metolazone—and/or infection was documented in 10 episodes.
At diagnosis of RF, all pts presented with normotension (mean 134/75
mm Hg) and anemia (mean hematocrit 30.1%). Five were febrile (4 with
infection). Those with infection (7) had a leucocytosis (17.3 x 109!nl vs.
8.3 x l09/nl in non-infected pts), only one had eosinophilia. Pyuria was
present concomitant with urinary tract infection, hematuria (without
dysmorphic red cells) in 5 infected and 2 non-infected cases, mild
proteinuria (mean 0.8 g/liter) in 8 and marked proteinuria (3.1 glliter) in
one. The maximum serum creatinine (Sr) ranged from 486 to 1124
jsmol/liter (mean 784). Sonographic kidney size was normal in all pts.
Dialysis was necessary in 7. Complete recovery of renal function was
observed after only 2 episodes. In 3 slight (mean 139) and in 6
moderate to severe (mean Scr 331 molIliter) impairment of renal
function was documented. One pt remained on dialysis, I died (cerebral
hemorrhage) and one resumed dialysis after 16 months. The degree of
interstitial fibrosis on biopsy correlated with clinical outcome. Conclu-
sions: The clinical presentation of IN was quite variable. The classical
signs (fever, rash, eosinophilia) were not seen in these pts; rather a
history of drug intake and/or infection, renal failure, anemia, mild
proteinuria were characteristic. Complete recovery of renal function
occurred only in a minority of the cases.
Tubulointerstitial nephropathy (TIN) in 2 HIV-infected patients con-
suming organic germanium (Ge) compounds. B. Hess, M. Blatter, J.
Raisin, F.F. Horber, C. Descoeudres, Ph. Jaeger, Medizinische Uni-
versitätspoliklinik, Inseispital, 3010 Bern, Switzerland. Based on anec-
dotal reports from Japan, Ge-containing compounds are increasingly
consumed as "natural" remedies; they are believed to increase the
body's defense against various diseases. We report on 2 HIV-patients
who developed TIN following intake of high doses of Ge-lactate-citrate
18% (Ge-Lac-Cit) for 9 months. Case 1. Following the advice of her
psychologist, a 25-year-old woman with stage II HIV disease had been
taking 3- to 10-fold the recommended doses of Ge-Lac-Cit during 9
months. Total Ge-Lac-Cit intake was about 260 g (47 g of Ge). She
sought for medical help because of severe fatigue, weight loss, nausea
and chronic diarrhea. Serum creatinine (Sr), initially 408 prnollliter,
rose to 866 mol/liter within 20 days; creatinine clearance (Ccr) was 7.0
mllminll.73 m2, proteinuria 0.28 glday. Uric acid (S) was 872
prnol/liter, Hb 9.1 g/dl, Her 0.24, and bone marrow biopsy showed
hyporegeneration. The patient was admitted to this hospital; a renal
biopsy revealed no glomerular abnormalities but vacuolar degeneration
of tubular epithelia with PAS-positive intracellular granular deposits
and few intraluminal proteinaceous casts. Focal lymphoplasmocytic
infiltration was noted in the interstitium. Despite hemodialysis, emesis
and abdominal pain persisted; severe hepatomegaly was documented at
sonography, and liver biopsy revealed massive steatosis. Analysis of
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the patient's hair disclosed a Ge-content of >143 ppm (normal: 0.2 to
0.4). Two months later, the patient has not yet recovered from renal
failure and remains on maintenance hemodialysis. Case 2. This 26-year-
old male homosexual with stage III HIV-infection, a friend of patient I,
had taken the same amount of Ge-Lac-Cit. He was feeling well but
came to check for nephropathy after discontinuing Ge-intake 2 weeks
earlier, when he heard of patient 1. was 212 mol/liter (259
smolI1iter one week later), urea 20.9 mmol/liter, and SUA 654 smol/
liter. Cc was 42.8 mI/mm/I .73 m2 (36.7 after 1 week), and proteinuria
0.36 g/day (<0.15 g/day after 1 week). Renal biopsy revealed no
glomerular abnormalities, but focal tubular atrophy with vacuolar
degeneration, PAS-positive intracellular granules and few intraluminal
proteinaceous casts. Peritubular lymphocytic infiltrates were rarely
seen. Comments: Since there seems to be a growing demand for
"health" products among patients with severe chronic diseases,
nephropathy associated with regular intake of high doses of Ge might
occur with increasing frequency. Therefore, physicians should be
aware of this syndrome, inasmuch as renal dysfunction appears to be
only partly reversible.
Lithium clearance in patients with chronic renal diseases. N. Clericetti,
C. Beretra-Piccoli, Ospedale Italiano di Lugano, Viganello, Switzer-
land. The clearance of lithium was analyzed in relation to glomerular
filtration rates and effective renal plasma flow in 41 patients with renal
disease and various degrees of renal functional impairment compared to
40 normal subjects. In the patients, there was on average a 35%
decrease in glomerular filtration rate (109 64 SD mI/mm) and renal
plasma flow (490 275 mI/mm) and a 25% decrease in lithium clearance
(22 12 mI/mm); lithium clearance correlated closely with glomerular
filtration rates and renal plasma flow (r = 0.69; P < 0.001). Absolute
proximal reabsorption of fluid was decreased by 38% (89 56 mI/mm)
while the distal absolute reabsorption of sodium (21 12 mI/mm) was
unchanged. Individual values of fractional proximal or distal reabsorp-
tion in relation to glomerular filtration rate or renal plasma flow were
equally distributed between normal and renal subjects, except in the
presence of a severe renal functional impairment, where both variables
decreased exponentially. This suggests that in renal failure, sodium
balance is maintained by a proportional decrease of proximal and distal
sodium reabsorption in relation to glomerular filtration. Only in the
presence of severe renal failure (GFR < 30 mI/mm) are both variables
concomitantly readjusted to lower values.
CLI deposition with respect to NEO-C9 and S-protein in renal biopsies.
L.E. French, J. Tschopp, J. Schifferli, Department of Medicine,
University Hospital, Geneva, Switzerland. The C5b-9 portion of the
complement system is known to mediate glomerular injury in various
models of experimental immune complex nephritis, and is suspected to
do so in equivalent clinical conditions. Since the discovery of 2
inhibitors of the membrane attack complex (MAC), CLI and S-protein,
there have been studies suggesting that the MAC seen within the
glomerulus in these pathologies represents deposition of cytolytically
inactive SC5b-9 shown to contain both these inhibitors. Using standard
immunofluorescence techniques, we studied 47 renal biopsies from
patients with the following diagnoses: lupus (13), IgA (3) and idiopathic
(8) glomerulonephritis, renal transplants (9), tubulointerstitial nephritis(2), cyclosporine treatment (3) and others (9). Study of the renal
glomerulus shows Neo-C9 deposits associated with CLI and S-protein
in 15 cases, without either CLI or S-protein in 3 cases, and without both
inhibitors in 23 cases. In the remaining 6/47 biopsies, no glomerulus was
seen. Never was CLI or S-protein seen in the absence of Neo-C9.
Interestingly, biopsies of renal transplants showed marked fluorescence
for Neo-C9 (8/9 cases) within the renal vessel walls, both inhibitors
being absent in 5/8 transplants. We conclude that Neo-C9 deposition
within the glomerulus of the biopsies studied is not always co-localized
with CLI and S-protein, suggesting that the visualized MAC is not only
in the cytolytically inactive form (SC5b-9).
Renal stone disease and chronic renal failure due to small bowel
resection. D. Kiss, R. Meier, K. Gyr, W. Wegmann, Medizinische
Klinik, Kantonsspital, und Kantonales Institut für Pathologic, Liestal,
Switzerland. A 58-year-old female patient with a 40 year history of
Crohn's disease had obtained the usual drug treatment and had under-
gone ileocoecal resection. Nevertheless chronic diarrhea persisted.
Concomitantly calcium-oxalate stones in the urine were repeatedly
observed. Ultimately, progressive renal failure developed necessitating
chronic dialysis. No other cause of chronic renal failure could be found
in the patient except for the presence of calcium-oxalate stones.
Therefore an extensive investigation of the patient was performed to
elucidate the pathophysiological mechanism. Analysis revealed a se-
vere steatorrhea of 43.3 g/day (5-7 g/day), pronounced hyperoxaluria of
0.7 mmol/day (below 0.5 mmol/day), decreased vitamin B-l2 serum
concentration of 115 pmol/liter (125-500 pmol/liter) and a severe chronic
interstitial nephritis with intratubular and interstitial calcium oxalate
crystals in the renal biopsy. All other investigations were within normal
limits, in particular no activity of Crohn's disease could be found. In the
pathogenesis of renal stone disease the concentration of lithogenic
substances may play an important role. In the case of small bowel
resection there was an interruption of the enterohepatic bile-acid
circulation leading to a loss of bile salts and steatorrhea. Due to the loss
of bile salts, oxalate absorption was increased inducing hyperoxaluria.
The increased concentration of oxalate in the urine played the main role
in the pathogenesis of calcium oxalate stone formation. Secondary
oxalosis and bacterial infections lead to a chronic interstitial nephritis
and chronic renal failure. Conclusions: In case of small bowel resection,
digestive function must be investigated. If steatorrhea or other types of
malabsorption syndromes are observed, oxalate excretion should be
measured. To normalize oxalate absorption, drug and dietary therapy
must be performed to prevent calcium oxalate stone formation and
ultimately renal failure.
Evidence for relative hypoparathyroidism in hypercalciuric versus
normocalciuric idiopathic calcium renal stone formers (SF). B. Hess,
J.-P. Casez, P. Angst, D. Ackermann, E. Zingg, Ph. Jaeger, Mediz-
inische und Urologische Universitàtspolikliniken, Inseispital, 3010
Bern, Switzerland. In the past, PTH has been reported to be elevated in
some hypercalciuric SF (HCSF), a finding not reproduced with next
generation PTH assays. The recent development of an immunoradio-
metric assay for intact PTH prompted us to readdress this issue.
Forty-nine male SF underwent metabolic evaluation on free-choice diet
(diet history, fasting blood and urine, two 24-hr urines, bone mineral
density [BMD] measurements). Intact PTH and blood Ca were
determined in all SF who were divided into HCSF (N = 24, UaV 10.8
0.5 mmol/day) and normocalciurics (NCSF, N = 25, UaV 5.0 0.3
mmol/day, all values mean 5EM) according to the classical definition
(HCSF: UcaV > 7.5 mmol/day). BMD, measured using dual-energy
X-ray absorptiometry, was corrected for body surface and age; values
are % deviation ( BMD) from expected normal at lumbar spine, based
on 137 healthy Swiss recruits. Results: There were negative linear
correlations between serum intact PTH (normal: 10-65 pg/mI) and either
fasting calciuria (CaE, r = 0.30, P = 0.04) or UcaV (r = 0.39, P = 0.005)
in all SF. At identical levels of blood Ca (1.30 0.01 mmol/liter),
PTH was lower in HCSF than in NCSF (25.3 2.0 vs. 32.4 2.1 pg/mI,
P = 0.02), whereas CaE was higher (0.041 0.003 vs. 0.022 0.002
mmol/liter GF, P = 0.0001), as were the excretions of oxalate (393 40
vs. 294 26 mol/day, P = 0.04), magnesium (5.3 0.3 vs. 4.1 0.3
mmol/day, P = 0.003) and sodium (216 10 vs. 175 12 mmol/day, P
= 0.01). Age, numbers of passed/removed stones and UV were not
different between subgroups, and Ca intake from dairy products (ques-
tionnaire) was similar (647 122 mg/day in HCSF vs. 563 90 mg/day
in NCSF, NS). Body weight was slightly higher in HCSF (79.6 2.2 kg
vs. 72.6 2.9 kg in NCSF, P = 0.056). Urinary excretion of indicators
of protein intake, urea (5.47 0.28 vs. 4.63 0.25 mmol/kg body wt,
P = 0.028) and sulfate (25.2 1.4 vs. 20.2 1.2 mmol, P = 0.008), were
higher in HCSF. Values of i BMDwere —4.5% in HCSF and —3.0% in
NCSF, respectively (NS). Daily urine volume was lower in NCSF (1627
95 vs. 2007 134 ml, P = 0.02). Conclusion: Relative hypo-, but not
hyperparathyroidism seems to characterize HCSF compared with
NCSF. Since both groups were apparently in steady state and had
similar Ca intake, intestinal Ca hyperabsorption of unknown mecha-
nism probably accounts for relatively PTH suppression and hypercal-
ciuria in HCSF.
Evolution of renal functions and histology in lupus nephropathy treated
by cyclosporin A and steroids. H. Favre, P.A. Miescher, R. Lemoine,
M.J. Mihatsch, Départements de Médecine et de Pathologic, Genève
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and Institut für Pathologie, Base!, Switzerland. Fourteen patients
suffering from SLE with renal involvement have been treated by
cyclosporin A (CsA) and steroids during aS year period. This treatment
was initiated after failure of conventional therapy (steroids and antime-
tabolites) given during a mean period of 48 7 months so. GFR and
RPF were measured after 2 and 5 years of CsA-steroid treatment at the
time a renal biopsy was performed. Clinical activity of the disease
slowed down during the first 6 months of treatment, and has since
stabilized in a quiescent phase characterized by an activity index below
7, except for 2 patients who have spontaneously discontinued their
treatment. Within 3 months SLE manifestations were reactivated in
these 2 patients. Histological activity index (A!) increased from 9 and 6
to 19 and 14 while GFR fell from 108 and 97 to 74 and 64 mI/mm,
respectively. The renal situation of the 12 patients still on treatment was
studied at 2 and 5 years: means SE Al 6.8 0.7 vs. 6.7 0.9 (NS);
chronicity index (CI) 4.9 0.7 vs. 7.5 0.8 (P < 0.05);GFR mI/mm 86
8 vs. 82 7 (NS); RPF mI/mm 471 34 vs. 453 43 (NS).
Spearman's rank correlation test gave a negative correlation between
RPF and CI; r = 0.419; P < 0.05. Although the disease appeared well
under control, the renal sclerosing process progressed in all patients.
The significant increase in CI was not correlated with AL nor GFR,
which remained unchanged. Decrease in RPF is the only functional
parameter accompanying the progression of irreversible lesions. Thus a
silent destruction of the kidneys, not related to the histological activity
of the disease, progressed slowly under this therapeutic regimen as has
been reported under other treatments. There was no evidence of CsA
nephrotoxicity in these patients. Relapse of the disease should be
expected on interruption of the treatment.
Comparison of biochemical and morphometric bone parameters in
chronic hemodialysis patients. D. Kiss, M.E. Kraenzlin, H.G. Flaas,
A.J. Olah, K. Gyr, Dialysestation, Medizinische Klinik, Kantonsspital,
Liestal; Endokrinologische Praxis, Base!; and Anatomisches Institut
der Universitat Bern, Switzerland. To diagnose renal osteodystrophy
(RO) and estimate its severity, intact parathyroid hormone (i-PTH),
osteocalcin (OC), alkaline phosphatase (AP), S-calcium (Ca) and
S-phosphorus (P) were measured in 23 chronic hemodialysis patients
(HD pts). In 8 pts with various degrees of RO a double tetracycline-
labeled iliac biopsy was performed and analyzed by histomorphometry
(HM). Comparison of static and dynamic HM-measures with the above
biochemical parameters revealed excellent positive correlations of
i-PTH with eroded bone surface (r = 0.97) as well as osteoclast surface
and number (r = 0.89 and r = 0.93, respectively). There was a rather
weak but significant correlation between OC and osteoblast surface (r =
0.64) and osteoid seam thickness (r = 0.63). AP correlated with mineral
apposition rate (r = 0.78) and osteoid surface (r 0.61). Furthermore,
a positive correlation was found between i-PTH and OC (r = 0.78) as
well as with AP (r = 0.61). In summary, i-PTH as well as biochemical
markers of bone turnover OC and AP correlated well with histomor-
phometric parameters in pts with RO. In conclusion, measurements of
biochemical markers of bone turnover can be used to determine the
degree of severity of RO in chronic HD pts.
Severe alwninium intoxication after prolonged abuse of aluminium
containing antiacids. F. Rohner, G. Jundt, P. Sandoz, Medizinische
Klinik, Burgerspital, CH-4500 Solothurn und Institut für Pathologic der
Universität, Base!, Switzerland. In the 70's aluminium-related enceph-
alopathy was the cause of death in about 50% of patients in hemodial-
ysis units affected by high aluminium in tap water. The elimination of
aluminium from dialysis fluids has greatly reduced the incidence of this
condition, We report a 47-year-old female patient with renal failure due
to analgesic nephropathy. Besides analgesics, the patient was known to
abuse barbiturates, benzodiazepines, laxatives and antiacids containing
aluminium hydroxide for many years. Anorexia mentalis was consid-
ered to be the underlying psychiatric disorder. About 6 months after
starting hemodialysis treatment the patient reported difficulty in con-
centration and poor memory, Gait ataxia, stuttering speech, tremor,
and asterixis were followed after a few weeks by intermittent motor
aphasia. Symptoms were considerably worse towards the end of
hemodialysis sessions and during the following day. Serum aluminium
concentration at this time was 330 sg/liter, normal value <27 g/1iter,
whereas the concentration in dialysis fluids was 0.54 and 1.08 tg/liter,
well below the recommended 10 sg/liter. Bone biopsy revealed un-
equivocal aluminium osteopathy and a bone aluminium content of 82.4
Mg'g wet weight. The patient was immediately advised to stop all
aluminium containing preparations. Subsequently she presented with
generalized tonic-clonic seizures usually occurring at the end of dialysis
sessions or shortly afterwards. The seizures were poorly controlled
despite vigorous medical treatment. Nine months after its initiation
hemodialysis treatment had to be stopped because of persistent arterial
hypotension, further weight loss and almost complete lack of patient
cooperation. Conclusions: In patients with renal failure the occurrence
of symptoms such as speech disorder, gait ataxia and seizures is
suggestive of aluminium intoxication. Despite elimination of aluminium
from dialysis fluids and less enthusiastic prescription of aluminium
hydroxide, aluminium intoxication remains a serious problem, particu-
larly in patients who take aluminium hydroxide in the form of over-the-
counter antiacids.
A controlled study of the effects of oral calcitriol (1,25D) therapy on
bone mineral density (BMD) in patients with end-stage renal failure
(ESRF). P. Ruedin, R. Rizzoli, D. S!osman, M.O. Guidat, M. Levy,
J.P. Bonjour, M. Leski, Divisions de Nephro!ogie, Physiopathologie
Clinique et Médecine Nucléaire, Hôpital Cantonal Universitaire, Gen-
eve, Switzerland. Chronic renal failure is associated with well known
qualitative bone alterations, for which high PTH levels play a major
pathogenic role. However, evolution of BMD at different skeletal sites
and response to 1 ,25D therapy, which is known to reduce PTH, are still
poorly documented in patients on chronic dialysis. Using dual photon
absorptiometry, we investigated the influence of 1 ,25D (0.25 jg/day) on
BMD at the level of lumbar spine (LS, CV: 2.1%), femoral neck (FN,
CV: 2.0%) and femoral shaft (FS, CV: 1.4%) in 21 patients (group A)
with ESRF (age: 56.2 3.6 years, x SEM, dialysis duration: 48.9
10.2 months) and compared them to 25 patients with ESRF who were
not treated with 1,25D (group B, age: 56.8 2.9 years, dialysis
duration: 32.1 8.2 months, NS) over a period of 20.3 1.5 and 17.2
1.2 months, respectively. Sex distribution, menopausal status, dial-
ysis bath calcium (Ca) and phosphate (Pi) binder therapy were similar in
both groups. PTH was measured with a mid-region assay (CV: 5.8%)
and osteocalcin by RIA (CV: 6.6%). During the study period, LS BMD
increased by 7.7 3.2%/yr in group A and decreased by 2.5 1.3%/yr
in group B (P < 0.005). FN BMD remained stable (+ 1.3 2.3 in group
A and —0.1 1.0%/year in group B). FS BMD increased more in group
A than in B (+6.7 2.3 vs. +1.4 2.0%/year, P < 0.05). Mean
monthly plasma Ca and Pi determinations were 2.35 0.02 and 2.43
0.02mmol/liter (P < 0.02), and 1.89 0.10 and 1.77 0.06 mmollliter,
in groups A and B, respectively. From initial values of 1417 208 and
1859 444 pmol/liter (normal < 135), PTH levels rose by 92 121 and
1033 254 pmollyear (P < 0.01) in groups A and B, respectively. Initial
osteocalcin levels were 48.8 7.8 and 44.2 5.8 pg/liter (normal <
13.5 pg/liter); differences of —2.7 3.7 and +20.1 11.7 sg/liter(P <
0.05) were detected per year in groups A and B, respectively. The
results of this controlled study indicate that 1 ,25D treatment of patients
with ESRF was associated with an increase of BMD at the levels of
lumbar spine and femoral shaft, and with a stabilization of PTH and
osteocalcin levels.
Erythrocytosis associated with acquired cystic disease of the kidney in
patients on maintenance hemodialysis. H. Jungbluth, K. Záruba, Nie-
renstation, Stadtspital Waid Zurich, Switzerland. Cystic transforma-
tion of the kidney may be a consequence of the progression of most
types of chronic kidney disease. We report four cases of acquired cystic
disease of the kidney (ACDK) in patients on maintenance hemodialysis
who developed erythrocytosis. Several years earlier, at the beginning of
dialysis treatment, all patients suffered from anemia, and three of them
needed blood transfusions. The underlying renal disease was chronic
pyelonephritis, chronic glomerulonephritis, Alport's syndrome, and
one patient had hypoplasia of the right, and hydronephrosis of the left
kidney. Three to seventeen years after the beginning of hemodialysis





dialysis Duration Highest levels Serum
of Hemo- Hemato- of Hemo- Hemato- erythro-
Case dialysis globin crit dialysis globin crit poietin
no. years gIdI % years g/dl % U/I
1 44 5.4 17 17 18.4 56 50
2 50 7.7 24 7 15.1 46 23.5
3 51 6.0 19 6 16.3 46 46.5
4 41 9.3 29 3 15.5 49 26
Serum erythropoietin (EPO) was measured by a radioimmunoassay
technique (normal range 8-22 U/liter), and found to be elevated (mean
36.6 U/liter). Using ultrasonography bilateral diffuse renal cystic trans-
formation could be demonstrated in all patients. Because of recurrent
thrombosis of the arteriovenous shunts, repeated blood-letting (the
disposal of extracorporeal blood after hemodialysis) was performed
until the hematocrit was 40%. We conclude that ACDK may be the
cause of EPO overproduction and erythrocytosis in dialysis patients.
Hemodialysis access: Experience with dual lumen catheters (C) surgi-
cally inserted in a central vein. C. Zehnder, Kantonsspital, Aarau,
Switzerland. This study presents our experience using surgically in-
serted double-lumen, silicone rubber, indwelling central venous C with
a subcutaneous Dacron cuff as a permanent or transitory access for
hemodialysis (HD). Fourteen C were placed in 11 patients (pts) (3 men)
aged 29 to 73 (mean 56 15) years. Seven were inserted via the right,
6 via the left internal jugular vein and I via the right subclavian vein.
Eight pts received 11 C as a permanent vascular access and 3 pts 3 C as
a temporary access. Permanent C were only chosen for long-term HD
pts (mean 76 48 months) with many previous vascular procedures(mean 6 2). All pts were anticoagulated. For connection to the
dialyzer the C were opened under sterile conditions. In 2/14 C postop-
erative local bleeding occurred. Ten of 11 C placed for permanent
access were removed after 0.3 to 42 (mean 13.7 13) months; C
survival was 12 months in 5, and of these 24 months in 2. One C without
complications is still in use after 20 months. The causes for removal
were: C sepsis 8 (6 S. aureus, 1 S. epidermidis, 1 E. coli) and C
thrombosis 2. One patient died from S. epidermidis septicemia with
endocarditis. Risk factors for infection—immunosuppressive therapy,
diabetes mellitus, iron overload—were documented in 5/8 pts. Subse-
quently 6/8 pts received a new "non-conventional" arterio-venous
fistula mainly in the thigh (3 femoro-saphenous fistulae). Three of 3 C
inserted as a transient access were used for 4 to 6 months without
complications. Conclusions: the surgical insertion of venous C for HD
is quite safe with a low rate of postoperative complications. However,
in our hands, long-term use of C was complicated by a high rate of
severe infections. In the majority of our pts an alternative access could
be found in spite of extensive previous surgery.
Pharmacokinetics of ofloxacin in CAPD. B. Rosenkranz, V. Malerc-
zyk, K. Zdruba, H. Jungbluth, N. Lameire, Clinical Research, Hoechst
AG, Frankfurt, Germany; Stadtspital Waid, Zurich, Switzerland; Uni-
versity Clinics Gent, Belgium. Ofloxacin is a quinolone antibiotic which
is characterized by complete oral bio-availability and 95% renal elimi-
nation. As a consequence its disposition is decreased in kidney disease
and dosage requires adjustment. About 20% of the dose is eliminated by
hemodialysis. In the present investigation, 6 patients (two male, four
female, age 24 to 75 years, body weight 46.6 to 73.0 kg) treated by
continuous ambulatory peritoneal dialysis (CAPD) received a single
oral dose of 200 mg ofloxacin. Drug concentrations were determined in
serum and dialysate. The pharmacokinetic results were as follows:
CAPD patients with peritonitis. In conclusion, CAPD contributes only
about 15% to the total elimination of ofloxacin in uremic patients.
Effective concentrations are attained in dialysate even after systemic
drug administration.
Urea kinetics in high flux hemodialysis. W. Probsi, C. Fikiocki, U.
Binswanger, Nephrologische Station, Departement Innere Medizin,
Universitiitsspital, Zurich, Switzerland. The quantification of hemodi-
alysis treatment is based on the calculation of the dialysis index (I) and
the protein catabolic rate (PCR) reflecting dietary protein intake in
steady state conditions. For determining I as proposed by the NCDS-
study (I = KT/V) and PCR it is necessary to know the urea distribution
volume (UDV). The latter was measured in 12 patients on high flux,
short-time hemodialysis treatment from collection of the dialysate and
measurement of pre- and postdialysis blood urea concentration. UDV
was compared after correcting postdialysis urea concentration for
rebound and for hemoconcentration, and after correcting for the urea
generation during dialysis treatment. The results are as followed:
UDV without corr. for urea
generation
UDV corrected for urea
generation
Urea corr. Without corr. Urea corr. Without corr.
for reb. + for reb. + for reb. + for reb. +
hemoconc. hemoconc. hemoconc. hemoconc.
38.32 6.86 38.66 6.74 36.28 6.51 36.61 6.40
The correction of postdialysis blood urea concentration was of minor
importance, whereas the UDV decreased by 5% after correction for
urea generation during dialysis treatment. This correction influences the
calculation of PCR and I, if estimated according to the NCDS study.
UDV calculated by use of the anthropomorphic formula of Watson
resulted in a value of 36.15 6.12 liters compared with 37.88 6.74
liters calculated as 0.58 x kg body weight. The correlation between our
measured and corrected values with those derived from the formula of
Watson was r 0.776 (P < 0.005).The latter procedure therefore seems
to fit best with requirements in daily practice.
The nature of transvascular fluid shifts during ultrafiltration treatment.
D. Schneditz, J. Roob, G. Haas, M. Moser, H. Pogglitsch, T. Kenner,
U. Binswanger, Physiologisches Institut, Medizinische Universitäts-
klinik Graz, Universität Graz, Austria; Nephrologische Station, Depar-
tement Innere Medizin, Universitdtsspital, Zurich, Switzerland. Fluid
losses from blood volume (BY) caused by ultrafiltration (UF) are to a
great extent refilled from the interstitial compartment of the extravas-
cular space. The protein concentration (ce) of refilling volume (Yrefihl)
was estimated and the hypothesis of considerable protein refilling (up to
25 g/liter in shifted volume; Hinghofer, Am J Physiol 250:1986) was
questioned. Density (D) of Vrefihl (Drefihl) was calculated from blood-D
(BD) and plasma-D (PD) determined at the beginning (index 1) and at
the end (index 2) of the removal of UF-volume (UFY) and from the
starting whole body hematocrit (hct) according to the formula: Drefihl =
((dBD PD2 — dPD BD2 (1 — hct))/(dBD — dPD (1 — hct)) (UFV
+ VrefiuI) — DUF UFV)/Vrefihl, where DUF is D of UFV and where dBD
and dPD is (BD2 — BD1) and (PD2 — PD1), respectively. BD was
determined from on-line measurements with an ultrasonic technique
and PD was determined by mechanical oscillator technique. The
investigation was made twice in 7 stable hemodialysis patients under-
going a continuous UF-period of 4 to 6 hours. Results (mean SD):
UF-rate = 10.8 3.7 ml/min, UFY = —2700 900 ml, Yrefihi = 2000
700 ml, Drefiul2OC = 1008.1 2.7 g/dm3, DUF = 1006.7 1.42 g/dm3,
relative change of BY = — 14.2 5.9%. From the relation between D
and plasma-cr (D20 = 1006.6 + 0.25 ci,) a mean c, of 6 g/liter was
calculated for Vrefihl. This c was explained by lymph backflow. Assum-
ing a mean 1ymph-c of 30 g/liter and a mean lymph flow of 85 mllhr,
almost 90% of protein refilling can be related to lymph flow. Therefore,
the major fraction of Vrenii entering the BY in the microcirculation by
backfiltration was supposed to be protein poor.
Epidemiology of peritonitis (P) during CAPD treatment by a double bag
system at one single institution. Tb. Thölen, M. Schmidli, N. Hofliger,
W. Probst, J. Wuest, G. Bichsel, U. Binswanger, Nephrologische
Cmax = 3.51 1.10 mg/liter, tmax = 1.71 0.81 hr,
AUDC = 133.3 64.0mg . hr/liter, CL/f = 29.3 11.2 mI/mm,V/f = 81.5 21.0 liter, t1,2 = 35.03 4.19 hr,
Ae (DIAL) = 28.6 9.2 mg, CL (DIAL) = 4.5 0.8 mI/mm.
Concentrations in dialysate paralleled those in serum. Both metabo-
lites, desmethyl-ofloxacin and its N-oxide, in serum and/or dialysate
were about 10% or less of the parent compound in two patients. Similar
results were obtained after i.v. administration of 200 mg ofioxacin in 7
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Station, Departement für Innere Medizin, Universitdtsspital Zurich,
Switzerland. A retrospective study of peritonitis during CAPD (>100
cells/mi of dialysate) between 1982 and 1989 using a double bag system
with cutting-sealing device (1 disconnection per exchange) revealed
monthly fluctuation of P rate between 0 and 15 events; the mean of
treatment months for observation of 1 episode were 10 (range 5 to 17
months). Peritonitis rate per patient reflecting population susceptibility
showed a decrease of 0 infections per patient from 16 to 9 per year; I
peritonitis per patient was stable at 9 episodes; more than 2 peritoniti-
des per patient and year increased from 1 to 9 episodes per year; this
finding might reflect a change of indications for the treatment mode. Of
special concern is the steady increase of culture negative "peritonitis"
from 3 to 25 events per year during the last 4 years in spite of special
efforts of diagnostic procedures. The percentage of dialysate samples
exhibiting less than 1000 cells per ml increased from 20 to 65% during
the last 2 years of observation. In conclusion, peritonitis is a major
problem in patients treated by a double bag system; patient selection
and maintenance of CAPD have to be modified. The high rate of culture
negative "inflammation" needs further study.
Surveillance of dietary protein prescription and intensity of dialysis
therapy during CAPD treatment. M. Schmidli, U. Binswanger, Neph-
rologische Station, Departement für Innere Medizin, Universitdtsspital
Zurich, Switzerland. Estimations of the protein catabolic rate (PCR)
(reflecting protein intake in steady state conditions) and calculation of a
dialysis index (Pent Dial Bull 3:152—156, 1985) were performed in 20
CAPD patients instructed to eat 1.0 to 1.5 g/kg body wt protein per day
and treated with 8 to 10 liter dialysate exchange per day. PCR was
based on nitrogen loss by dialysis and urine as well as by losses,
assumed to be constant, by stool and skin. Dialysis loss was obtained
either by collection of the 24-hour dialysate volume or by estimating the
equilibration ratio between blood and dialysate for calculation of
nitrogen removal from serum urea nitrogen and 24-hour dialysate
volume. Values obtained were 0.77 0.15 and 0.74 0.16, respec-
tively, r 0.84, P < 0.0001. These low PCR values were found to
correlate with data from dietary surveys. They could not be suspected
from low serum protein concentrations or low transferrin levels.
Dialysis indices were 1.20 0.44, 1.0 reflecting adequate treatment. It
is concluded that protein intake and dialysis adequacy have to be
monitored individually. Whereas generally recommended CAPD sched-
ules provide effective treatment, the recommended protein intake is
often not followed.
Outcome in critically ill patients with acute renal failure treated by
continuous hemofiltration. G. Keusch, P. Schreier, U. Binswanger,
Nephrologische Station, Departement für Innere Medizin, Universi-
tatsspital Zurich, Switzerland. Patients with acute renal failure (ARF)
and multiple organ failure still have a high mortality in spite of advances
in renal replacement therapy and other aspects of care. To evaluate
mortality rate and risk factors, a retrospective analysis of 49 intensive
care patients (aged 22 to 76 years) with ARF treated by spontaneous
arteno-venous (36 patients) or pump assisted venous-venous hemofil-
tration (13 patients) between 1984 and 1988 was carried out. At the
beginning of continuous hemofiltration the following complicating fac-
tors and vital function disorders were present (number of patients):
Mechanical ventilation (37), ARDS (16), vasopressor support (43),
septicemia (28). ARF occurred as a result of postoperative complica-
tions in 27 patients, multiple traumatic lesions in 8 patients, major burns
in 2 patients and internal medical reasons in 12 patients. Twenty out of
49 patients survived their episode of ARF, but only 18 patients (37%)
were discharged alive from the hospital. Septicemia complicating ARF
occurred more frequently in the non-survivor group (21 out of 32
patients) as compared to survivors (7 out of 18), P < 0.05. The cause of
death was related to septicemia in 14 patients, to multiorgan failure and
septicemia in 8 patients, to cardiovascular failure in 9 patients and to
hepatic failure in one patient. In conclusion, ARF in critically ill
patients still has a high mortality rate despite renal replacement therapy
with continuous hemofiltration; death is predominantly due to septice-
mia.
Efficacy of subcutaneous vs. intravenous maintenance therapy with
erythropoietm in chronic hemodialysis patients. H. Freudiger, Z. Glück,
Regionalspital, CH-2502 Bid, Switzerland. Whereas there is no doubt
about the efficacy of recombinant human erythropoietin (rHuEPO) on
the correction of renal anemia, the optimal route of its administration is
still a matter of debate. We therefore investigated the efficacy of
subcutaneously (s.c.) and intravenously (i.v.) applicated rHuEPO in 18
patients who were on i.v. rHuEPO maintenance therapy for at least 4
months. After a 2 month stabilization period (Hct change 4 points/2
mo), patients were assigned either to continue with i.v. rHuEPO (N =
8) or to be switched to s.c. rHuEPO (N = 10) while keeping the EPO
dose constant. Hct was measured at 4 week intervals. In each group, 2
patients were excluded for GI bleeding (Hct fall 5 points and positive
stools for blood andlor endoscopically proven bleeding source). Hct
values remained stable in both groups during the 20-week observation
period. Absolute values of Hct and rHuEPO dose were not significantly
different among the two groups and relative values of Hct (compared to
the mean value of the stabilization period) varied between 100% 12
and 104% 3 for the i.v. group and 100% 6 and 105% 6 for the s.c.
group (P:NS). Results: mean SD:
Stabili- 4 8 12 16 20
zation weeks weeks weeks weeks weeks
Hcti,v,% 31±2 32±2 31±3 31±3 31±2 32
Hcts.c.% 30±2 30±2 31±2 31±3 30±1 31
EPO dose i.v.
U/kg/week 143 54 137 61 138 62
EPO doses.c. 151 70 158 68 158 68
We conclude that in hemodialysis patients on maintenance therapy with
rHuEPO, the s.c. route of administration did not increase the efficacy of
the therapy and therefore no savings of the drug could be obtained.
Impact of dialysis modality on body composition in patients with
end-stage renal disease (ESRD). H. Saxenhofer, J. Scheidegger, Ph.
Jaeger, C. Descoeudres, F.F. Horber, Medizinische Universitdtspoli-
klinik und Institut für Diagnostische Radiologie der Universität Bern,
Switzerland. Loss of muscle mass and altered body fat distribution (i.e.
increased central fat stores in the presence of normal peripheral fat
stores) have been reported in patients on hemodialysis (MD), when
compared to normal volunteers. Whether treatment of ESRD with
chronic peritoneal dialysis (CPD) would alter body composition differ-
ently when compared to MD is unknown. To answer this question, two
groups of male patients with ESRD (HD: N = 11; CPD: N = 11) were
studied. Subjects were matched for age [MD: 51 3 years (mean
SEM); CPD 58 41, body weight (MD 73 4 kg; CPD 74 2), body
height (HD 170 1 cm; CPD 170 1) and physical activity. Muscle
mass and body fat distribution were assessed using computed tomog-
raphy. Mid-thigh muscle area was similar in both groups (HD: 106 8
cm2; CPD: 111 5). In addition, peripheral fat stores (as estimated by
mid-thigh fat area: HD: 58 5 cm2; CPD 51 5) and central fat stores
(as estimated by mediastinal fat area: MD 6.1 2.0 cm2; CPD 8.1 1.8)
were not different between the two groups of dialysis patients. In both
groups muscle mass and fat stores were independent of duration of
dialysis treatment, age, daily protein intake (range 44 to 75 g/day; only
assessed in CPD patients) and residual renal function. In CPD patients,
muscle area was correlated with plasma albumin (r 0.56, P < 0.05),
but not with plasma transferrin levels. In conclusion, the present results
indicate that both HD and CPD resulted in similar changes of body
composition. Neither central nor peripheral fat stores are increased in
CPD patients when compared to MD treated patients, despite a contin-
uous glucose load in the former group.
Effects of simvastatin on plasma lipid profile in patients undergoing
continuous peritoneal dialysis (CPD). H. Saxenhofer, P. Ferrari, W.F.
Riesen, C. Descoeudres, Medizinische Poliklinik der Universität Bern
und Institut für Klinische Chemie, Kantonsspital St. Gallen, Switzer-
land. The efficacy and safety of the HMG-CoA reductase inhibitor
simvastatin was assessed in 12 patients (56 9 years, mean SD) on
CPD for 24 7 months with plasma total cholesterol concentration
>8.0 mmol/liter. After a placebo period of 6 weeks, simvastatin 20
mg/day was administered as a single dose for 8 weeks, followed by a
wash-out period of 6 weeks during which the patients again received a
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placebo. Simvastatin therapy was associated with the following changes
in lipid parameters:
Plasma Placebo Simvastatin Placebo
Total cholesterol, mmol/!iter 9.84 0.60 6.24 0.46' 9.77 0.65
Triglycerides, mmol/!iter 4.17 0.30 3.13 0.33a 4.09 0.47
HDL-C, mmo!/liter 1.10 0.07 1.18 0.10 1.03 0.09
LDL-C, mmol/liter 6.53 0.53 3.59 0.37c 6.77 0.49
VLDL-C, mmol/liter 2.21 0.18 1.47 0.231 1.98 0.21
Apo B, g/!iter 2.42 0.15 1.61 0.12c 2.45 0.19
Apo A-I, glliter 1.56 0.09 1.63 0.14 1.41 0.07
Lipoprotein (a), U/liter 393 91 345 79 410 90
a P < 0.05; b P < 0.01; C p < 0.001 vs. placebo by ANOVA
Simvastatin was well tolerated. No serious clinical or laboratory
adverse effects were observed during the study. The data suggest
considerable therapeutic efficacy of simvastatin in the treatment of
hyperlipoproteinemia in CPD patients.
Long-term patient survival and causes of death after cadaveric kidney
transplantation. G. Keusch, F. Largiadêr, U. Binswanger, Nephrolo-
gische Station, Departement für Innere Medizin, Universitdtsspital,
8091 Zurich, Switzerland. At our institution 673 patients (pts) [mean age
41 17 (sn) years] received 773 cadaveric kidney allografts between
December 1964 and December 1983. In all pts basal immunosuppres-
sion consisted of azathioprine-prednisone. During 4 to 23 years (yrs) of
follow-up, 316 pts (47%) died. In 171 (54%) pts kidney graft was still
functioning at the time of death. Actuarial patient survival was 67% at
5 yrs, 54% at 10 yrs and 26% at 20 yrs, respectively. The half life of
survival (natural logarithm of 2 divided by the slope of the linear
regression line of the logarithmic transformed data points) was 13.9 yrs.
The survival rates at 10 yrs among the different age groups were as
follows: age 16 to 40 years (N = 327) 67%; age 41 to 50 yrs (N 194)
41%; age over 50 yrs (N = 152) 39%. Causes of death included:
infections in 117 pts (37%), cerebro- and cardiovascular complications
in 81 pts (26%), malignant neoplasms in 32 pts (10%). During the first
year following transplantation infection was the leading cause of death
and was responsible for 70 (52%) of 135 deaths in this period. In
contrast the predominant causes of death in the late post-transplant
period (>5 yrs after transplantation) were cerebro- and cardiovascular
complications (25%), malignant neoplasms (21%), infections (20%) and
liver cirrhosis (10%).
Additive effects of prednisone (PRED) and cyclosporin A (C5A) therapy
on serum cholesterol (SC) in renal transplant patients (RTP): Effect of
time interval after kidney transplantation (KT) and therapy with fibrates.
J.A. Fuhrer, A. Montandon, C. Descoeudres, Ph. Jaeger, F.F. Horber,
Medizinische Universitàtspoliklinik, Inse!spital, Bern, Switzerland. By-
percholesterolemia in RTP is claimed to be preferentially induced by
PRED therapy. However, short term therapy with CsA was associated
with increased SC at least in non-RTP, Thus it is unclear to what extent
different immunosuppressive regimens contribute to increased SC
observed in RTP after prolonged periods of immunosuppression (i.e., 3
and 5 years after KT). Therefore, RTP were evaluated with respect to
SC 3 years (N = 103) and 5 years (N = 66) after KT. RTP with diabetic
nephropathy, nephrotic syndrome and hypothyroidism were excluded.
RTP were divided in two groups (GR): GR-l, PRED/azathioprine
(AZA) (3 years, N = 52; 5 years, N = 49); GR-2, PRED and/or CsA (3
years, N 51; 5 years, N = 17). GR were similar with respect to age,
sex, body mass index, underlying diseases, renal function and concom-
itant drug therapy. PRED dose was higher in GR-l (3 years, 13 I
mg/day; 5 years, 11 1; mean 5EM) than in GR-2 (3 years, 3 1; 5
years, 4 2 mg/day, P < 0.01). SC was persistently higher in RTP of
GR-2 when compared to GR-1 (3 years, 7.3 0.2 vs. 6.7 0.2 mM, P
<0.01; 5 years, 7.5 0.1 vs. 6.6 0.3; P <0.01) despite lower daily
PRED doses in CsA treated RTP (GR-2). Therapy with fibrates and diet
(N = 33) decreased SC in RTP of GR-1 (N = 15; therapy duration 66
7 months) and GR-2 (N = 18, therapy duration 33 4 months) from 8.1
0.4 to 7.0 0.3 (P = 0.02) and from 9.6 0.4 to 7.0 0.3 (P <0.001),
respectively. In summary: SC is increased in RTP irrespective of their
immunosuppressive treatment and remains elevated to the same extent
after 3 and 5 years of treatment. RTP treated with CsA alone or with
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CsA/PRED have higher SC than RTP on AZA/PRED treatment. In
addition RTP may be effectively and safely treated with various
fibrates. These results suggest: 1) an independent hypercholesterolemic
influence of CsA; and 2) that PRED and CsA may have an additive
impact on SC.
C-reactive protein and detection of early renal graft rejection. D.
Evéquoz, J. Rosman, W. Rohrer, J. Landmann, G. Thiel, Departement
Innere Medizin, Abt. für Nephrologie, und Departement Chirurgie,
Universitätskliniken, CH-4031 Base!, Switzerland. Twenty-four pa-
tients were monitored daily for C-reactive protein in serum during the
first 28 days after kidney transplantation. Immunosuppressive therapy
consisted of steroids and azathioprine from the first day on, either ATG
or OKT3 during the first 7 days and cyclosporin A starting the 4th day.
Group A consisted of 7 patients who showed no signs of infection or
complication until discharge. Then a rapid normalization of the CRP
levels was noticed. The 7 patients of Group B had to be treated against
rejection. The CRP levels showed a sharp incline and correction after
improvement of renal function following anti-rejection therapy. The 5
patients of Group C presented with clinical signs of infection which
necessitated anti-bacterial or anti-viral therapy. The infections occurred
principally in the very early phase after transplantation before the
expected normalization of CRP levels, as demonstrated in Group A.
Hence, these pre-infection CRP levels can not be interpreted as
increases in preclinical infections. Group D consisted of 5 patients
without clinical evidence of infection or rejection. Four of them
developed a clinical condition that explained a CRP rise (infarction of
the transplant, iatrogenic injury of the pyelon, recurrence of cryoglob-
ulinemia, bioptic verified osmotic nephrosis). In this group one rise in
CRP remained unexplained and normalized after 4 days. We conclude
that in spite of aggressive immunosuppressive therapy a CRP rise
without clinical infection or evidence of another pathology should raise
suspicion of graft rejection.
Lipid abnormalities after renal transplantation: Are they cyclosporine
associated? J. Rosman, D. Evequoz, J. Landmann, G. Thiel, Departe-
ment Innere Medizin, Abt. für Nephro!ogie und Departement of Chir-
urgie, Universitätskliniken Kantonsspita! Base!, 4031 Base!, Switzer-
land. Alterations in lipid metabolism are common findings after renal
transplantation. Literature is conflicting regarding the causal back-
grounds. We performed lipid analyses in 244 transplanted patients and
related the findings to the immunosuppressive therapeutic modalities
and antihypertensive therapy. Four groups were created: C (cyclospo-
rifle monotherapy), CP (cyclosporine-prednisone), CA (cyclosporine-
azathioprine) and CAP (triple therapy). The findings were compared
with the results obtained in patients on conventional immunosuppres-
sive therapy: AP (azathioprine-prednisone). Thirteen individuals, who
already were on lipid-lowering drug therapy were excluded from the
calculations (5 in group C, 5 in group AP and 3 in group CAP). Results:
All groups had comparable body weight, blood pressure, proteinuria
and distribution of age and sex. Median creatinine clearance was lowest
in group CAP (43 mI/mm) and comparable in the other groups (53 to 63
mI/mm). Median values of lipid profiles are presented in the Table.
AP C CP CA CAP
N 59 84 20 19 49
Years after TPL 9.2 3.9" 49b 26b 28b
Cholesterol
mmol/liter 6.92 6.2P' 7.02 6.58 7.08
Triglycerides
mmol/!iter 1.74 2.40 2.33 1.92 2.63"
HDL 1.53 1.23" 1.20k' 20b
LDL 4.49 4.19 4.75 4.95 4.87
VLDL 0.62 0.76a 0.77 0.94 O.88a
Mann-Whitney U-test: a P < 0.05; b P < 0.01, compared with the
AP-group.
Cyclosporine containing regimes caused no changes in total cholesterol,
lowered HDL and increased VLDL. However, a strong correlation was
found between general deterioration of lipid profile and the use of
diuretics and beta blockers. The latter agents should be used with
caution in the treatment of the hypertensive transplanted patient.
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Benefit of annual check.up in detecting malignant tumors after renal
transplantation. W. Rohrer, H.A. Bock, G. Thiel, Abteilung Nephrolo-
gie, Kantonsspital Base!, Switzerland. Traditionally, our kidney trans-
plant recipients have been given an annual, broadly based check-up
comprising a complete physical examination, dermatological and gyne-
cological examinations, a biochemical screening (including immune
electrophoresis), CBC, chest X-ray and urine cytology. We retrospec-
tively evaluated the benefit of these check-ups in detecting post-
transplantation malignancies for the period from 1967 to 1990. Check-
ups were performed in 464 of the 666 patients transplanted during this
time (a total of over 2300 check-ups) and 90 malignant tumors were






Basalioma/spinalioma 25 13 40
Melanoma 3 1 4
Urothelial carcinoma 4 10 14
Lymphomaileukemia — 10 10
Colorectal carcinoma — 3 3
Cervical carcinoma 3 — 3
Other 3 13 16
Total 38 52 90
Patients with tumor 20 46 66
Died from tumor 3 25 28
Lethality 15% 54% 42%
Tumor lethality was significantly lower in the 20 patients whose tumor
was detected at check-up than in the other 46 patients (P < 0.005).
Potentially, 34 of the 38 tumors detected at check-up could have been
detected by combining a dermatological and gynecological examination
with urine cytology. Chest X-ray and the biochemical screening did not
contribute to tumor detection. In conclusion, annual check-ups contrib-
ute significantly to the early detection of malignant tumors after kidney
transplantation. They may favorably affect post-transplantation tumor
mortality. However, with the studies used so far, they do not help in
detecting some typical post-transplantation tumors such as lymphoma
and leukemia.
Clinico-pathological studies on cyclosporine (CsA) associated arterio-
lopathy in renal transplantation. K. Morozumi, T. Oikawa, A. Yoshida,
T. Fujinami, K. Kodera, A. Takeda, K. Koyama, K. Uchida, M.J.
Mihatsch, Department of Medicine III, Nagoya City University Medi-
cal School, Department of Nephrology and Transplantation, Nagoya
Second Red Cross Hospital, Japan; and Department of Pathology,
University of Baste, Base!, Switzerland. CsA nephrotoxicity is divided
into tubulopathy and arteriolopathy (CAA). Although morphologic
findings and diagnostic criteria of CAA are well studied, clinical
interpretation and progression of CAA are still controversial. The
present study was performed to investigate the clinical features, pro-
gression/regression of CAA and the prognosis of grafts with CAA. Of
213 renal allograft patients who were using CsA therapy from 1982, 188
graft biopsies were performed to investigate the cause of deteriorated
graft function and proteinuria. Trough levels of whole blood CsA were
strictly monitored to maintain levels of approximately 100 ng/ml (by
high-performance liquid chromatography). Twenty specimens out of 17
patients revealed typical CAA. Eleven recipients had deteriorated graft
function and 8 proteinuria at the time of biopsy. Typical hemolytic
uremic syndrome-like vascular lesions were found in one case. The time
diagnosing CAA ranged from one to 53 post-operative months (mean;
15.5 months). The mean trough level and administrated dose of CsA
were 131 ng/ml and 292 mg/day at the time of biopsy, respectively.
Acute rejection in 7 cases, chronic rejection in two cases and glomer-
ulonephritis in three cases were concomitantly diagnosed in typical
CAA cases. The main reason for graft dysfunction seemed to be
rejection or glomerulonephritis rather than CAA. Although four cases
required re-hemodialysis, eleven cases had rather good function during
the follow-up period (mean: 20 months). Prognosis of the isolated CAA
case was fairly good, Remodeling of the arteriolar wall maintaining
patency of the lumen seems to play an important role in the Outcome of
CAA which does not lead to graft failure. We concluded that low dose
CsA therapy was a safe therapy in kidney transplantation even in cases
with typical CAA.
Two rare forms of renal involvement in plasma cell dyscrasia; POEMS
syndrome associated glomerular lesion and crystal deposit disease. K.
Morozumi, K. Sugito, A. Takeda, J. Aoki, T. Suganuma, A. Yoshida,
T. Fujinami, M.J. Mihatsch, Department of Medicine III, Nagoya City
University Medical School, Nagoya, Japan; and Department of Pa-
thology, University of BasIc, Base!, Switzerland. Cast nephropathy,
amyloidosis and light chain deposit disease are well recognized renal
manifestations in plasma cell dyscrasia. New and rare renal lesions
were recently noticed in plasma cell dyscrasia. POEMS syndrome was
diagnosed in a 49-year-old female who had complaints of dyspnea and
edema, developed neuropathy of extremities (polyneuropathy), hepato-
splenomegaly and huge kidneys (organomegaly), hypothyroidism (en-
docrinopathy), IgG lambda (M-protein) and skin pigmentation (skin
changes). No proteinuria and hematuria were found. Light and electron
microscopy showed diffusely prominent irregular thickening of the tufts
and mesangiolysis with expanded subendothelial space. No amyloid
fibrils and immuno-deposits were found. Crystal deposit disease was
diagnosed in a 64-year-old man with complaints of numbness of the legs
who developed proteinuria and tubular injuries. Bence Jones protein
IgU kappa was detected in serum and urine. Bone marrow study and
bone X-ray showed no sign of multiple myeloma. Remarkably swollen
tubular and glomerular epithelial cells filled with numerous rhombic
crystalline deposits that were negative for lgG and light chain were
observed by light and electron microscopy. The same crystals were also
found in mesangial cells. In a new classification of renal lesions in
plasma cell dyscrasia and in multiple myeloma, POEMS syndrome-
associated glomerular lesion and crystal deposit disease should be
included as separate disease entities.
Chronic dialysis in elderly patients. Analysis of outcome in patients
aged over 75 years. S. David, J.-G. Pannatier, J.-P. Wauters, Division
of Nephrology, University Hospital, CH-lOll Lausanne, Switzerland.
Therapy of ESRF in elderly patients has raised ethical and financial
concerns. Therefore we reviewed our experience in treating patients
aged 75 years at the initiation of therapy, Among 276 patients entering
our hemodialysis program from 1980 to 1989 (average 60 new patients/
yr/lU8 population), 15 were aged between 75 and 81 years. The etiology
of renal failure was: nephroangiosclerosis (3), multiple myeloma (3),
interstitial nephritis (3), analgesic nephropathy (2), glomerulonephritis
(1), diabetic nephropathy (I), polycystic kidneys (1), and renal tuber-
culosis (1). After initiation of dialysis, only 8 patients out of 15 had to be
hospitalized (mean 43 days, range 2 to 190 days), mostly for cardiovas-
cular reasons. Actuarial survival rate was 80% at 3 years, comparable to
the overall hemodialysis population. Dialysis was stopped in one
patient after 3 years and 3 months because of a severe dementia. Eight
patients are still alive, only one is living in an institution. Based on our
experience, age alone should not be considered as a criterion to decline
chronic dialysis to elderly patients.
Delayed decrease in filtration reserve after unilateral nephrectomy.
B.M. Regazzoni, J.-P. Guignard, G.S. Arbus, N. Genton, Départe-
ments de Pediatric et de Chirurgie pediatrique, CHUV, loll Lausanne,
Switzerland. Evidence has been produced that a reduction in the renal
functional mass first causes glomerular hyperfilti-ation in the remnant
nephrons, a phenomenon that can ultimately lead to pathologic glomer-
ular lesions and consequent deterioration of glomerular filtration. To
test this hypothesis the renal response to acute oral protein loading was
studied in 37 patients uninephrectomized during childhood, up to 29
years before the study. Indications for nephrectomy were: multicystic
dysplasia, ureteral stenosis and severe renal scarring. Seven healthy
adults were used as controls. They all had 2 kidneys and were matched
for age with patients whose follow-up after uninephrectomy was longer
than 10 years. Creatinine clearance, measured on alternate years, had
remained stable in all patients throughout the follow-up period. Results:
The filtration reserve, as measured by the increase in inulin clearance
following an acute protein load, was identical in the recently uninephrec-
tomized patients and in the control group (+28.7 9.9 and +30.1
10.3%), while it progressively declined with time in the patients
followed for more than 10 years after nninephrectomy. In the 14
patients uninephrectomized more than 20 years before the study, the
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increase in GFR was significantly reduced (+9.7 12.6%) as compared
to controls (P < 0.005), while baseline GFR and renal blood flow (PAH
clearance) were similar in both groups. The filtration reserve amounted
to at least 10 mllmin in that control group and in all recently (<10 years)
uninephrectomized patients. By contrast, 36% of the patients followed
for more than 20 years responded to protein loading by actually
lowering their GFR. We conclude that the acute protein loading test is
a valuable test for unveiling covert functional renal damage following
loss of renal mass, long before the appearance of proteinuria or
hypertension.
Renal hemodynamic and functional changes induced by interleukin-1 in
the rabbit. A. Pedrotti, B.M. Assael, J.-P. Guignard, Service de
Pédiatrie, CHUV, 1011 Lausanne, Switzerland. Recent experimental
evidence suggests that the polypeptide interleukin-l (IL-l) mediates
several hemodynamic and renal changes observed during infection. The
administration of IL-i has been shown to induce a shock-like state in
the rabbit, as well as natriuresis and diuresis in the rat. The specific
mechanisms responsible for the diuretic and natriuretic effect of IL-i
have not been fully elucidated. It may affect renal function indirectly, as
a response to decreased blood pressure, or directly, as a direct
natriuretic effect. The renal effects of a bolus intravenous injection of
human recombinant IL-I-beta were studied in anesthetized and me-
chanically-ventilated rabbits, administered 0.5 (N 9) and 5 (N = 8)
pg/kg body wt of IL-I. Untreated control rabbits receiving the vehicle
alone (N = 9) showed no changes in renal hemodynamics and function
throughout the 3-hour experimental period. A rapid decrease in sys-
temic blood pressure occurred in IL-i treated rabbits, from 99.2 3.4
to 82.9 3.5mm Hg (0.5 pg/kg) and from 99.3 4.1 to 69.5 4.8mm
Hg (5 gig/kg). Rectal temperature increased + 1.85°C (0.5 gig/kg) and
+0.85°C (5 pg/kg) at the end of the experimental period. Diuresis
increased +41.9% (0.5 sgIkg) and +38.8% (5 pg/kg). Fractional sodium
excretion (FENa) increased +79.6% (0.5 pg/kg) and +42.7% (5 pg/kg).
FE and FEK also rose. Inulin clearance fell — 17.7% (0.5 pg/kg) and
—34% (5 zg/kg). Renal blood flow, as measured by PAH clearance,
increased +16.4% (0.5 pg/kg) and +18.1% (5 pg/kg), along with
increased diuresis and sodium excretion. Filtration fraction rose and
renal vascular resistance fell significantly. These results demonstrate
that IL-l induces hemodynamic changes similar to those observed in
septic shock, associated with increases in renal blood flow, urine flow
rate and sodium excretion, features also often observed during infec-
tion. In an additional experimental group of 5 rabbits, the injection of
100 ng of IL-i in the left renal artery did not produce any change in
diuresis and natriuresis in that kidney, nor in systemic blood pressure.
These preliminary results suggest that the IL-I does not directly affect
water and sodium excretion.
Potassium transtubular gradient in newborn infants: Its relation to
metabolic acidosis, aldosterone and prostaglandin E2 excretion. E. Su-
lyok, K. Adamovich, T. fawn, H. W. Seyberth, J.-P. Guignard, County
Children's Hospital, Pécs, Hungary and Service de Pédiatrie, CHUV,
Lausanne, Switzerland. The transtubular potassium concentration gra-
dient (TTKG), calculated as K} urine: (urine/plasma) osmolality/[K1
venous blood, has been shown to reliably reflect aldosterone bioactivity
in infants and children. The present study was undertaken to define the
metabolic acidosis-induced changes in renal potassium handling and
their relation to the urinary excretion of aldosterone and PGE2 excre-
tion in newborn infants undergoing mild metabolic acidosis. Birth
weight and gestational age of 7 infants included in this study ranged
from 1300 to 3750 g (mean: 2164 g) and from 28 to 40 weeks (mean: 34
weeks), respectively. Ammonium chloride loading was performed with
a single dose of 2.8 mmol/kg NH4C1 given at the end of the first week of
life. Blood acid-base parameters, plasma electrolytes and osmolality as
well as renal functions including TFKG, potassium excretion and urine
NaIK ratio were measured prior to and following NH4CI administration.
The latter parameters were related to the excretion of aldosterone (as
measured by RIA) and PGE2 (as measured by gas chromatographic
mass spectrometry). TTKG was lower in neonates as compared to older
infants and adults. In response to metabolic acidosis, TTKG tended to
increase (2.21 0.31 vs. 2.74 0.55). TTKG was positively related to
the daily excretion of aldosterone (r = 0.84, P < 0.001), independently
of acid-base balance. TFKG did not correlate with the excretion of
PGE2. It is concluded that aldosterone plays a direct regulatory role in
the control of distal tubular potassium handling in human neonates.
Such a role could not be established for PGE2.
Renal effects of dopexamine, a new dopaminergic agonist, in the
newborn rabbit. T. Jaton, M. Thonney, J.-B. Gouyon, J.-P. Guignard,
Service de Pédiatrie, CHUV, 1011 Lausanne, Switzerland. Dopamine is
frequently used in premature infants presenting with respiratory dis-
tress syndrome, incipient cardiovascular failure and/or acute renal
insufficiency. This drug, when given at high doses, as often required,
may induce a deleterious vasoconstriction due to a-adrenergic vascular
receptor stimulation. Recently, a new dopaminergic agonist, dopexam-
me, has been produced, which is devoid of any a-adrenergic effect and
has marked /32-adrenergic and dopaminergic agonist properties. We
studied the renal effects of dopexamine in 8 anaesthetized, mechanical-
ly-ventilated newborn rabbits, an animal model whose renal functional
characteristics show close similarities with those of premature infants.
Glomerular filtration rate (GFR) and renal plasma flow (RPF) were
assessed by the clearance of inulin and PAH, respectively. After a
control period, dopexamine was infused intravenously at a rate of 4
pg/kg per mm for 40 mm; following a 20-mm washout period, the same
drug was again infused at a higher rate of 10 pg/kg per mm for 40 mm.
Blood gases and pH remained stable throughout the experiment, while
the hematocrit decreased slightly. Dopexamine, 4 pg/kg per mm, did
not induce changes in renal functions, heart rate or mean arterial
pressure, which remained stable at 32 mm Hg. When given at a rate of
10 pg/kg per mm, a significant increase in urine flow rate (+25 5%; P
<0.01), urine sodium excretion (+77 17%; P < 0.01) and fractional
excretion (+69 25%; P < 0.05) was observed. GFR (mi/kg per mm),
RPF (mi/kg per mm) and RVR (mm Hg/mi per kg. mm) remained stable
with values of 2.49, 16.8 and 1.39, respectively. Heart rate increased
slightly but significantly (+8 3%; P < 0.05), without change in mean
arterial pressure. The natriuretic and diuretic effect of dopexamine in
normal immature rabbits, in the absence of changes in RPF or GFR, is
probably mediated by a direct action of this agent on the dopaminergic
tubular receptors. The potential usefulness of dopexamine on the
neonatal stressed kidney, when vasoconstriction predominates, is pres-
ently under investigation.
The Basle experience in living-related donor kidney transplantation,
1967 to 1990. B. Huser, J. Landmann, M. Rist, F. Brunner, G. Thiel,
Departments of Internal Medicine and Surgery, Kantonsspital Basel,
Switzerland. Between July 12, 1967 and April 1, 1990 a total of 649
kidney transplants were performed at our institution (560 first, 80
second, 8 third and 1 fifth transplants). Living related donors were used
for 55 patients (49 first, 4 second and 2 third transplants). Donors were
parents in 28 cases, siblings in 26 cases and a 58-year-old grandmother
in one case. HLA typing showed full identity in 14 pairs (including one
pair of monozygotic twins) and one haplotype identity in 33 cases. Since
1983 all recipients (living related and cadaveric) received prophylactic
immunosuppressive treatment with cyclosporine. The minimal obser-
vation time was 6 months for all recipients and ranged up to 20 years for
living related transplants and up to 23 years for cadaveric transplants,
respectively. Results: As expected, transplant survival was better for
living donor grafts with 94% at 1 and 72% at 5 years compared to
cadaveric grafts with 73% at 1 and 52% at 5 years. Patient survival at I
and 5 years was 98% and 82% for living related graft recipients versus
90% and 72% for recipients of cadaveric grafts. Thirty-nine out of 41
recipients of living related kidneys transplanted since January 1, 1985,
currently have a functioning graft (one graft loss after 5 years due to
recurrence of glomerulonephritis, one death secondary to infectious
complications in a recipient of a third transplant). Living donor mor-
bidity was low (1 pulmonary embolism, 1 superficial phlebothrombosis,
minor wound problems). Conclusion: Results of living-related kidney
transplantation have been quite satisfactory and donor morbidity low.
Although not strictly comparable to cadaveric transplantation, living
related donation continues to be an excellent option for patients with
end-stage renal disease.
